A Randomized Open Label Phase 1/2 Study of INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared To Daratumumab SC, in Participants With Relapsed or Refractory Multiple Myeloma
Laufzeit: 01.01.2024 - 31.12.2022
imported
Kurzfassung
-